- Home
- PBYI vs CCCC Comparison
PBYI vs CCCC Comparison
Compare PBYI & CCCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PBYI
- CCCC
- Stock Information
- Founded
- PBYI 2010
- CCCC 2015
- Country
- PBYI United States
- CCCC United States
- Employees
- PBYI N/A
- CCCC N/A
- Industry
- PBYI Biotechnology: Pharmaceutical Preparations
- CCCC Biotechnology: Pharmaceutical Preparations
- Sector
- PBYI Health Care
- CCCC Health Care
- Exchange
- PBYI Nasdaq
- CCCC Nasdaq
- Market Cap
- PBYI 171.7M
- CCCC 175.1M
- IPO Year
- PBYI N/A
- CCCC 2020
- Fundamental
- Price
- PBYI $4.64
- CCCC $3.57
- Analyst Decision
- PBYI Strong Buy
- CCCC Strong Buy
- Analyst Count
- PBYI 1
- CCCC 3
- Target Price
- PBYI $7.00
- CCCC $8.67
- AVG Volume (30 Days)
- PBYI 648.1K
- CCCC 1.4M
- Earning Date
- PBYI 11-06-2025
- CCCC 10-30-2025
- Dividend Yield
- PBYI N/A
- CCCC N/A
- EPS Growth
- PBYI 434.29
- CCCC N/A
- EPS
- PBYI 0.97
- CCCC N/A
- Revenue
- PBYI $238,062,000.00
- CCCC $34,240,000.00
- Revenue This Year
- PBYI N/A
- CCCC N/A
- Revenue Next Year
- PBYI N/A
- CCCC N/A
- P/E Ratio
- PBYI $4.76
- CCCC N/A
- Revenue Growth
- PBYI 8.63
- CCCC 16.55
- 52 Week Low
- PBYI $2.32
- CCCC $1.09
- 52 Week High
- PBYI $6.07
- CCCC $7.14
- Technical
- Relative Strength Index (RSI)
- PBYI 49.99
- CCCC 77.23
- Support Level
- PBYI $4.49
- CCCC $2.58
- Resistance Level
- PBYI $5.22
- CCCC $2.75
- Average True Range (ATR)
- PBYI 0.26
- CCCC 0.21
- MACD
- PBYI -0.12
- CCCC 0.04
- Stochastic Oscillator
- PBYI 22.33
- CCCC 94.66
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis resulting into apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.
About CCCC C4 Therapeutics Inc.
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients' lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. Its degrader medicines are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT1946, and CFT8919.